Skip to main content

Day: April 29, 2020

Husky Energy Announces First Quarter 2020 Dividend and Second Quarter 2020 Preferred Shares Dividend Payments

CALGARY, Alberta, April 29, 2020 (GLOBE NEWSWIRE) — Husky Energy’s Board of Directors has approved a reduction to the quarterly dividend to $0.0125 (Cdn) per common share for the three-month period ended March 31, 2020.The dividend will be payable on July 2, 2020 to shareholders of record at the close of business on June 9, 2020.Regular dividend payments on each of the Cumulative Redeemable Preferred Shares – Series 1, Series 2, Series 3, Series 5 and Series 7 – will be paid for the three-month period ended June 30, 2020. The dividends will be payable on June 30, 2020 to holders of record at the close of business on June 9, 2020.Investor and Media Inquiries:Kim Guttormson, Manager, Communication Services403-298-7088

Continue reading

Cowen Announces First Quarter 2020 Financial Results

Reports 1Q20 GAAP Loss of $(0.41) per share and Economic Operating Loss of $(0.24) per shareRecord Quarterly Brokerage Revenues and Second-Highest Investment Banking RevenuesOperating Co Segment Profitable Despite Losses in Investment Income and Incentive IncomeAsset Co Segment Losses Due to Markdowns in Private PortfolioStrong Balance Sheet with Reduced Risk, Book Value of $24.74 and TBV of $18.60 per share.NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) — Cowen Inc. (NASDAQ: COWN) (“Cowen” or “the Company”) today announced its operating results for the first quarter ended March 31, 2020.Jeffrey M. Solomon, Chairman and Chief Executive Officer of Cowen, said, “Even though the first quarter of 2020 was the most challenging period for financial markets in more than a decade, Cowen performed well operationally. We had very strong...

Continue reading

resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology

Combined Company to Focus on Adicet’s Technology and Continue Operations as “Adicet Bio”Adicet’s lead asset ADI-001 is an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor targeting CD20 for treatment of non-Hodgkin’s lymphomaPipeline of differentiated pre-clinical and discovery programs leveraging universal, off-the-shelf gamma delta CAR-T cells and novel antibody platformsWell capitalized into 2022 to develop novel cell therapiesBOSTON and MENLO PARK, Calif., April 29, 2020 (GLOBE NEWSWIRE) — resTORbio, Inc. (Nasdaq: TORC) and Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that they have entered into a definitive merger agreement to create a combined publicly-traded biotechnology company focused on the development of Adicet’s off-the-shelf allogeneic gamma delta T cell...

Continue reading

Rockridge Drills 28.0 g/t Gold Over 6.0 Metres at 95 Metres Vertical Depth in New High Grade Discovery at its Raney Gold Project, SW of Timmins, Ontario

VANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) — Rockridge Resources Ltd. (TSX-V: ROCK) (OTCQB: RRRLF) (Frankfurt: RR0) (“Rockridge” or the “Company”) announces that it has completed nine diamond drill holes in a 2,070-metre diamond drilling program at its Raney Gold Project located southwest of Timmins, Ontario, Canada (the “Raney Gold Project” or “Property”). Assays have been received for the first six holes, with a highlight intercept of 28.0 g/t gold over 6.0 metres (uncut).Raney Gold Project Location Map:http://www.rockridgeresourcesltd.com/_resources/maps/location_map_raney.pdfHighlights:The Raney Gold Project is a large prospective gold property covering 1,417 hectares located ~110 km southwest of the prolific gold district of Timmins, ONThe drilling program entailed 2,070 metres in nine diamond drill holes;...

Continue reading

Celestica Announces First Quarter 2020 Financial Results

(All amounts in U.S. dollars. Per share information based on diluted hares outstanding unless otherwise noted.)TORONTO, April 29, 2020 (GLOBE NEWSWIRE) — Celestica Inc. (TSX: CLS)(NYSE: CLS), a leader in design, manufacturing and supply chain solutions for the world’s most innovative companies, today announced financial results for the quarter ended March 31, 2020 (Q1 2020).Q1 2020 HighlightsRevenue: $1.32 billion, decreased 8% compared to $1.43 billion for the first quarter of 2019 (Q1 2019).Operating margin (non-IFRS)*: 2.9%, compared to 2.4% for Q1 2019.Advanced Technology Solutions (ATS) segment revenue**: decreased 5% compared to Q1 2019, and represented 41% of total revenue, compared to 40% of total revenue for Q1 2019; ATS segment margin** was 2.7%, compared to 2.6% for Q1 2019.Connectivity & Cloud Solutions (CCS)...

Continue reading

Akoustis Achieves Design Lock and Ships Its Drone XBAW Filter

– Company’s 12th Commercially Available XBAW Filter –– New Drone Filter was Designed and Shipped to Customer Within Three Months –– Company Rapidly Expanding Its Filter Product Portfolio for Multiple Wireless Markets –Charlotte, N.C., April 29, 2020 (GLOBE NEWSWIRE) — Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today it has achieved design lock and shipped its C-band filter for the drone market supporting unmanned aircraft systems (UAS). The filters will be used for control and non-payload communication (CNPC) links.This announcement marks the 12th design locked XBAWTM filter that Akoustis has produced, a six-fold increase in catalog filters in the last...

Continue reading

Orchard Therapeutics Announces Eight Presentations Across Gene Therapy Portfolio at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting

Most Comprehensive Presentation of Orchard Clinical Data to Date; Spans Five Disease Areas and Highlights Broad Applicability of Hematopoietic Stem Cell Gene Therapy ApproachAccepted Abstracts Include Data on Investigational Gene Therapies for Neurometabolic Conditions, Including Updated Interim Data from Proof-of-Concept Trial in OTL-203 for Mucopolysaccharidosis Type IBOSTON and LONDON, April 29, 2020 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced eight upcoming presentations from across its neurometabolic, primary immune deficiency and blood disorder franchises at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting, which will take place online May 12-15, 2020, marking the company’s most comprehensive presentation of clinical data at a medical meeting...

Continue reading

ADMA Biologics to Report First Quarter 2020 Financial Results on May 6, 2020

RAMSEY, N.J. and BOCA RATON, Fla., April 29, 2020 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and for the prevention of certain infectious diseases, today announced that it will report financial results for the first quarter ended March 31, 2020 on Wednesday, May 6, 2020 after the U.S. financial markets close.  ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.To access the conference call, please dial (855) 884-8773 (local) or (615) 622-8043 (international) at least 10 minutes prior to the start...

Continue reading

Costamare Inc. Reports Results for the First Quarter Ended March 31, 2020

MONACO, April 29, 2020 (GLOBE NEWSWIRE) — Costamare Inc. (“Costamare” or the “Company”) (NYSE: CMRE) today reported unaudited financial results for the first quarter ended March 31, 2020 (“Q1 2020”).Net Income of $32.8 million or $0.21 per share in Q1 2020.Adjusted Net Income available to common stockholders(1) of $32.6 million or $0.27 per share in Q1 2020.Voyage Revenues of $121.4 million.Liquidity of $268.4 million as of end Q1 2020 (including our share of cash amounting to $31.0 million held in subsidiaries co-owned with York Capital Management Global Advisors LLC and an affiliated fund (collectively, together with the funds it manages or advises, “York”)).No material balloon payments in 2020(2).Chartered in total 12 vessels over the quarter.Declared dividend of $0.10 per share on its common stock and dividends on all four classes...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.